Studies

Non-metastatic

Currently no open trials

Metastatic

First line
Currently no open trials

Second line
IDeate-Lung02 (Daichi Sankyo) (DS7300-188)
A phase 3, multicenter, randomized,open-label study of ifinatamab deruxtecan (idxd), a b7-h3 antibody-drug conjugate (adc), versus treatment of physician’s choice (topotecan) in subjects with relapsed small cell lung cancer

EVOKE-SCLC-04 (Gilead)
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan (antibody-drug conjugate targeting TROP2) Versus Standard of Care (SOC) in Participants With PreviouslyTreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Resectable

Neo-coast2 (Astra Zeneca)
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer

KRASG12c + NSCLC: SUNRAY-02 (Lilly)
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Pts with Resected or Unresectable KRAS G12C-Mutant, NSCLC (JZQH)

Unresectable

SUNRAY-02 (Lilly) : open September 2026
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Pts with Resected or Unresectable KRAS G12C-Mutant, NSCLC (JZQH)

1st line

Squamous and non-squamous

Artemide (Astra Zeneca)
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig (bispecific antibody, anti PDL1 en anti-TIGIT) or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Rosetta Lung-02 (Biontech): open August 2026
A Phase II/III, multisite, randomized master protocol for a global trial of Pumitamig (bispecific antibody, anti PDL1 en anti-VEGF) in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer

Non-squamous
Relativity CA224-1093 (BMS)
A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab (anti-LAG-3) Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Nonsmall Cell Lung Cancer and with Tumor Cell PD-L1 Expression ≥ 1%

AndroMETa M24-536 (ABBVIE): part 2 open end of 2025
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 (telisotuzumab adizutecan, c-Met-targeting antibody-drug conjugate) in Combination with Budigalimab (anti-PD1) in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536) 

Pulse: maintenance (academic)
Maintenance Pembrolizumab at usual or low dose non-squamous lung cancer: a non-inferiority study.

2nd + line

Artemia (OSE Immunotherapeutics)
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 (Tedopi®) versus docetaxel in HLA-A2 positive patients with metastatic NonSmall Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitors (ICI)

RAINFOL-05 (GCT1184-05 , Genmab)
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (antibody-drug conjugate targeting folate receptor alpha) in Participants with Non-Small Cell Lung Cancer. 

All actionable genomic alteration

(ie, ALK, RET, ROS1 rearrangement, KRAS G12C, BRAF mutations, and MET exon 14 skipping mutations/MET,amplification, and HER2 mutations)

2nd + line

RAINFOL-05 (GCT1184-05 , Genmab)
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (antibody-drug conjugate targeting folate receptor alpha) in Participants with Non-Small Cell Lung Cancer. 

EGFR common exon 19 or exon 21 mutation

1st line
LAT-FLOSI (Academic)
LAT (Local ablative therapy) for Oligoprogressive NSCLC Treated With First-line OSImertinib (LATFLOSI).

2nd + line
TROPION-LUNG15 (Astra Zeneca)
A Study to Investigate the Efficacy and Safety of Dato-DXd (Datopotamab deruxtecan, antibody-drug conjugate targeting TROP2) With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

RAINFOL-05 (GCT1184-05 , Genmab)
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (antibody-drug conjugate targeting folate receptor alpha) in Participants with Non-Small Cell Lung Cancer. 

EGFR exon 20 insertion mutation

1st line
Currently no open trials

2nd + line
RAINFOL-05 (GCT1184-05 , Genmab)
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (antibody-drug conjugate targeting folate receptor alpha) in Participants with Non-Small Cell Lung Cancer. 

HER2 mutation

1st line
SOHO-2 Bayer
A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered sevabertinib (BAY 2927088) Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC With HER2-activating Mutations.

MET exon 14 skipping mutation

Currently no open trials

(K)RAS mutation

1st line
KRASCENDO 170 (Roche): cohortes C & D open April 2026
Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of divarasib in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a kras g12c mutation
Currently no cohorts open

Krascendo2 (Roche)
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Krascendo 2)

2nd + line
All RAS mutations
RASolve 301 (RMC-6236-301, Revolution Medicine)
Phase 3 Multicenter, Open Label, Randomized Study of daraxonrasib (RMC-6236) Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

RAINFOL-05 (GCT1184-05 , Genmab)
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (antibody-drug conjugate targeting folate receptor alpha) in Participants with Non-Small Cell Lung Cancer. 

ALK fusion

1st line
Currently no open trials

2nd + line

RAINFOL-05 (GCT1184-05 , Genmab)
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (antibody-drug conjugate targeting folate receptor alpha) in Participants with Non-Small Cell Lung Cancer. 

BRAF mutation

1st line
Currently no open trials

2nd + line

RAINFOL-05 (GCT1184-05 , Genmab)
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (antibody-drug conjugate targeting folate receptor alpha) in Participants with Non-Small Cell Lung Cancer. 

Other trials

Currently no other open trials

Delphi 312 (Amgen)

A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and  Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

REZILIENT 3 (Taiho Oncology) 

Randomized, Controlled, Open-label, Phase 3, Global MultiCenter Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
 

ASPIRE

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic Cough.

TILIA

A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)